Targeted Skin-Lightening Composition With Encapsulated Kojic Acid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved skin-lightening compositions that provide safe and effective depigmentation without undesirable adverse effects, particularly through synergistic combinations of active ingredients that minimize the use of toxic substances.
Innovation Solution
A cosmetic composition comprising sclareolide, kojic acid encapsulated within a melanocortin 1 receptor (MC1R) agonist peptide-containing microcapsules or nanocapsules, and ascorbyl glucoside, which synergistically enhance skin-lightening effects while reducing the amount of each active ingredient needed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of active ingredients are used in skin-lightening cosmetic products, then depigmentation efficacy is improved, but adverse effects increase
Solution Approach 1:
The patent combines three active ingredients (sclareolide, kojic acid, and ascorbyl glucoside) in specific concentrations to achieve synergistic depigmentation effects. This combination allows the formulation to reach higher efficacy than individual ingredients at high concentrations would provide alone, while maintaining lower overall concentrations to reduce adverse effects.
Solution Approach 2:
The patent optimizes the concentration parameters of each active ingredient within specific ranges (sclareolide: 0.01-5%, kojic acid: 0.001-1%, ascorbyl glucoside: 0.1-10%) to achieve the desired balance between efficacy and safety. By precisely controlling these parameters, the formulation maximizes depigmentation while minimizing irritation and other adverse effects.
2Object-affected harmful factors
If reduced amounts of active ingredients are used, then adverse effects are minimized, but depigmentation efficacy decreases
Solution Approach 1:
The synergistic combination of sclareolide, kojic acid, and ascorbyl glucoside allows the formulation to achieve high depigmentation efficacy even at reduced concentrations. The combined effect of these three ingredients working through different mechanisms compensates for the lower individual concentrations, maintaining efficacy while reducing adverse effects.
Solution Approach 2:
The patent creates a composite cosmetic formulation that integrates multiple active ingredients with complementary mechanisms of action. This composite approach allows the system to achieve superior performance at lower concentrations compared to single-ingredient formulations, resolving the contradiction between reduced dosage and maintained efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves enhanced whitening effects with reduced amounts of active agents, minimizing adverse effects and improving cellular viability and depigmentation efficacy in an in vitro model.
Implementation Method 1
kojic acid encapsulated within a microcapsule or nanocapsule comprising a peptide of formula (I)... wherein the peptide is coupled to the outer surface of the microcapsule or nanocapsule
Data Source
AI summary
The present invention relates to a cosmetic skin lightening composition comprising the combination of sclareolide, kojic acid and ascorbyl glucoside, wherein kojic acid is encapsulated within a targeted microcapsule or nanocapsule having a melanocortin 1 receptor (MC1R) agonist peptide bound to the surface. It was found that such combination of active substances provided synergistic kin-whitening effect. The present invention also relates to the cosmetic use of this composition for skin whitening, particularly, for the elimination or reduction of hyperpigmented marks of the skin, such as UV exposure related marks, post-scar marks, post-inflammation marks, melasma marks, lentigo marks or age-related marks.